首页 克利夫兰生物实验室(usCBLI)-基本信息

克利夫兰生物实验室(usCBLI)-基本信息

日报更新时间:

周报更新时间:01-23 11:54

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

中文名称:克利夫兰生物实验室


英文名称:Cleveland BioLabs


行业:服务业


简介:Cleveland Biolabs, Inc.是一家临床阶段的生物技术公司,该公司致力于研发一系列疗法,包括抗癌治疗,针对肿瘤患者的支持性护理疗法和针对急性辐射综合症的医疗措施,该措施一般基于细胞死亡的调制


电话:1-716-8496810


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Cleveland BioLabs, Inc.是一家生物制药公司,在美国和俄罗斯开发新方法来激活免疫系统并满足各种医疗需求。克利夫兰生物实验室专利的Toll-like免疫受体激活剂(TLR)平台可用于辐射缓解,肿瘤免疫治疗和疫苗。Cleveland BioLabs公司的候选产品是entolimod,一种免疫激动剂,可用作医学辐射对策和肿瘤学及其他适应症的免疫疗法。Cleveland BioLabs开发中项目包括CBLB612,这是一项临床前研究,一种合成分子,可激活toll-like异二聚体受体2/6并刺激白细胞的产生;并已完成 II 期临床,治疗接受阿霉素 - 环磷酰胺化疗的乳腺癌患者的骨髓抑制预防。克利夫兰生物实验室公司还在开发Mobilan,一种重组非复制型腺病毒,可指导TLR5及其激动配体的表达。Cleveland BioLabs与克利夫兰诊所(Cleveland Clinic)和罗斯威尔公园癌症研究所(Roswell Park Cancer Institute)建立了战略合作伙伴关系。

交易日期 交易人 职位 类型 交易份额 价格
2015-02-24 Saluck (Randy S) Director Buy 1891 3.42

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Advisor Group, Inc. 25 -- -- -- 2019-03-31
USAA Asset Management Company 2800 0.02% -- -- 2019-07-31
Royal Bank of Canada 3631 0.03% -- -- 2019-03-31
Northern Trust Investments Inc 7222 0.06% 18 0.25% 2019-07-31
BlackRock Inc 13629 0.12% -896 -6.17% 2019-03-31
Fidelity Management & Research Company 16939 0.15% -- -- 2019-07-31
Vanguard Investments Australia Ltd 37796 0.33% -- -- 2019-07-31
Vanguard Group Inc 106674 0.94% -- -- 2019-03-31
Renaissance Technologies Corp 293416 2.60% 6100 2.12% 2019-03-31
SunAmerica Asset Management, LLC 2200 0.02% -- -- 2019-07-31
FMG LLC 775 0.01% -- -- 2019-07-31
BlackRock Fund Advisors 741 0.01% -1795 -70.78% 2019-07-31
BlackRock Asset Management Canada Ltd 31 -- 29 1450.00% 2019-07-31
BMO Asset Management Inc 31 -- -- -- 2019-03-31
Bank of Montreal 31 -- -- -- 2019-03-31
Wells Fargo & Co 46 -- -2 -4.17% 2019-03-31
Group One Trading, LP 68 -- -- -- 2019-03-31
Bank of America Corporation 150 -- -- -- 2019-03-31
Ladenburg Thalmann FI Services Inc 265 -- -- -- 2019-03-31
State Street Global Advisors 633 0.01% -- -- 2019-07-31
Mellon Investments Corporation 138 -- -821 -85.61% 2019-07-31
Bessemer Investment Management LLC 425 -- 425 -- 2018-12-31
Bessemer Group Inc 425 -- 425 -- 2018-12-31
IFP Advisors, Inc 150 -- -- -- 2018-12-31
Geode Capital Management, LLC 33376 0.30% 16688 100.00% 2018-12-31
UBS Group AG 5981 0.05% 3925 190.90% 2018-12-31
Susquehanna Financial Group, LLLP 15268 0.14% -12042 -44.09% 2018-12-31
Susquehanna International Group, LLP 15268 0.14% -12042 -44.09% 2018-12-31
Stratos Wealth Partners, LTD 100 -- 100 -- 2018-09-30
FAF Advisors Inc 100 -- -- -- 2018-09-30
US Bancorp 100 -- -- -- 2018-09-30
Invesco Capital Management LLC 1030 0.01% -- -- 2019-01-31
BNY Mellon Asset Management North America Corporation 157 -- 157 -- 2018-11-30
Vanguard 445 -- -- -- 2018-11-30
Citadel Advisors Llc 15389 0.14% 1888 13.98% 2018-06-30
UBS Securities LLC 1370 0.01% -2560 -65.14% 2018-06-30
Wells Fargo Advisors, LLC 200 -- -- -- 2018-09-30
Sabby Management LLC 149876 1.33% -708724 -82.54% 2017-12-31
Guggenheim Funds Investment Advisors LLC 1274 0.01% -- -- 2018-09-14
Mellon Capital Management Corporation 644 0.01% 157 32.24% 2018-06-30
Merrill Lynch & Co Inc 100 -- -- -- 2018-06-30
Ladenburg Thalmann Asset Management Inc 20 -- -- -- 2018-06-30
Deutsche Bank AG 4 -- -- -- 2018-06-30
Panagora Asset Management Inc 10427 0.09% 10427 -- 2017-12-31
Morgan Stanley Smith Barney LLC 50 -- -- -- 2017-12-31
Winfield Associates Inc 500 -- -- -- 2017-09-30
BlackRock Advisors LLC 2800 0.02% -- -- 2018-01-31
Thompson Davis & Co Inc 1334 0.01% 334 33.40% 2017-09-30
TWO SIGMA SECURITIES, LLC 10495 0.09% 10495 -- 2017-06-30
KCG AMERICAS LLC 52091 0.46% 38233 275.89% 2017-06-30
Tower Research Capital LLC 599 0.01% 599 -- 2016-09-30
SB Auer Funds, LLC 72000 0.66% -- -- 2016-12-31
Pine River Capital Management, L.P. 150000 1.37% -- -- 2016-09-30
Alpha Capital Anstalt 703463 6.40% 417360 145.88% 2016-02-03
Prudential Insurance Co of America 60 -- -- -- 2015-12-31
Sabby Management, LLC 460687 2.00% 1492626 0.10% 1999-11-30
Mikhail Mogutov, Ph.D. 264318 2.00% 856390 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
iShares Core Balanced ETF Portfolio 2 -- 2 -- 2019-07-30
Vanguard Total Stock Market Index Fund 37796 0.33% -- -- 2019-06-30
Vanguard Extended Market Index Fund 13546 0.12% -- -- 2019-06-30
NT Ext Equity Market Index Fund - L 6051 0.05% -- -- 2019-06-30
USAA Extended Market Index Fund 2800 0.02% -- -- 2019-06-30
SAST SA T. Rowe Price Asset Allc Gr Port 2200 0.02% -- -- 2019-05-31
Vanguard US Equity Index Fund 1532 0.01% -- -- 2019-06-30
Fidelity 1303 0.01% -- -- 2019-06-30
1290 VT Micro Cap Portfolio 775 0.01% -- -- 2019-05-31
iShares Core S&P Total US Stock Mkt ETF 741 0.01% -- -- 2019-07-30
State Street U.S. Extended Market Index 633 0.01% -- -- 2019-06-30
iShares Core S&P US Total Mkt ETF CADH 2 -- -- -- 2019-07-31
iShares Core Growth ETF Portfolio 3 -- 3 -- 2019-07-30
iShares Core S&P US Total Market ETF 23 -- 23 -- 2019-07-30
NT US Market Cap Index Fund - NL 40 -- -- -- 2018-12-31
NT Ext Equity Mkt Fd - DC - NL 253 -- 18 7.66% 2019-06-30
NT Extended Equity Market Idx Fund - NL 353 -- -- -- 2019-06-30
NT US Market Cap Index Fund - Lending 525 -- -- -- 2019-06-30
iShares Core MSCI AllCntry Wld exCan ETF 1 -- 1 -- 2019-07-30
BNYM Mellon SL Mkt Completion Fd 138 -- -349 -71.66% 2019-03-31
NT Ext Equity Mkt Idx Fd - DC - NL 253 -- 18 7.66% 2019-06-30
BNYM Mellon NSL Mkt Completion Fd Instl 472 -- 472 -- 2019-03-31
iShares Micro-Cap ETF 3460 0.03% -10509 -75.23% 2019-06-28
BNYM Mellon NSL Market Completion Fund 472 -- 472 -- 2019-03-31
Invesco Wilshire Micro-Cap ETF -- -- -1030 -100.00% 2019-02-22
BNYM Mellon SL Market Completion Fund 138 -- -349 -71.66% 2019-03-31
BNY Mellon Market Completion Fund -- -- -157 -100.00% 2018-12-31
Master Extended Market Index Series -- -- -2800 -100.00% 2018-02-28
Vanguard Total Stock Mkt Idx 155269 1.37% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 13546 0.12% -- -- 2018-07-31
iShares Micro-Cap 13265 0.11% -- -- 2018-09-12
Fidelity Spartan 1776 0.02% -- -- 2018-07-31
Wilshire Micro-Cap ETF 1274 0.01% -- -- 2018-09-14
AXA/Lord Abbett Micro Cap K 775 0.01% -- -- 2018-07-31
iShares Core S&P Total US Stock Mkt 741 0.01% -- -- 2018-09-12
USAA Extended Market Index 2800 0.02% -- -- 2018-07-31
QMA Wilshire 5000 Indexing CF 60 -- -- -- 2018-03-31
BNY Mellon Market Completion Fund UC1 157 -- 157 -- 2018-03-31
SSgA U.S. Total Market Index Fd Class I 177 -- -12 -6.35% 2017-12-31
BNY Mellon EB DL Mkt Completion 487 -- -- -- 2018-06-30
The Vanguard Total Stock Market Index 445 -- -- -- 2017-12-31
Auer Growth 72000 0.66% -- -- 2016-12-31
Wilshire 5000 Indexing Tr 60 -- -- -- 2015-06-30
Fidelity Spartan® Extended Mkt Indx Fd 10000 0.10% 5307 113.10% 2015-09-30
The Vanguard - Total Stk Mkt Idx Trust. CF 445 -- -- -- 2015-10-31
Mellon Capital EB DL Mkt Completion Fund 618 -- -- -- 2015-09-30
Vanguard US Equity Index 1532 -- -- -- 2015-07-31
Fidelity Spartan® Total Market Idx Fund 1776 -- -- -- 2015-09-30
Fidelity® NASDAQ Composite Index® Fund 161 -- -- -- 2015-09-30

Andrei V. Gudkov Andrei V. Gudkov is an entrepreneur who founded Cleveland BioLabs, Inc., OncoTartis LLC and Everon Biosciences, Inc. He holds the position of Director & Chief Scientific Advisor at Panacela Labs, Inc., Chief Scientific Officer of OncoTartis LLC, Chief Scientific Officer for Everon Biosciences, Inc., Chief Science Officer at Genome Protection, Inc. and Chief Scientific Officer of Cleveland BioLabs, Inc. Andrei V. Gudkov is also on the board of Incuron LLC. Dr. Gudkov previously was Principal at National Cancer Research Center, Chairman-Molecular Biology Department at Cleveland Clinic Lerner Research Institute, Faculty Member at the University of Illinois, Chairman-Cell Stress Biology Department at Roswell Park Comprehensive Cancer Center and Professor at Case Western Reserve University. He received a doctorate from Moscow State University Lomonosov and a doctorate from N N Blokhin Russian Cancer Research Center.
Yakov Kogan Founder of Cleveland BioLabs, Inc., Yakov Kogan holds the position of Chief Executive Officer for Panacela Labs, Inc., CEO, Principal Financial Officer & Secretary at Cleveland BioLabs, Inc., Chief Operations Officer of Genome Protection, Inc. and Director & Principal Business Officer at Kadvax Technologies, Inc. In his past career Dr. Kogan was Senior Scientist at ThermoGen, Inc., Director-Business Development for Integrated Genomics, Inc. and Research Associate at The University of Chicago. He received a graduate degree and a doctorate from Moscow State University, an MBA from The University of Chicago Booth School of Business and a doctorate from VNII Ekonomiki Selskogo Khozaystva.
Langdon L. Miller Langdon L. Miller holds the position of President & Chief Medical Officer at Cleveland BioLabs, Inc. and Chief Medical Officer & Executive Vice President at VelosBio, Inc. He is also on the board of Dunn Gardens. He previously held the position of Chief Medical Officer for PTC Therapeutics, Inc., Vice President-Clinical Research Oncology at Gilead Sciences, Inc. and Executive Vice President-Research & Development at Calistoga Pharmaceuticals, Inc. (a subsidiary of Gilead Sciences, Inc.), Vice President-Global Clinical Research at Pharmacia Corp. and Principal at National Cancer Institute. He received a doctorate from Northwestern University.
Randy Steven Saluck Founder of Mortar Rock Capital Management LLC, Randy Steven Saluck presently holds the position of Chief Executive Officer of Libertas Funding LLC and Chief Financial Officer & Director at Convexity Scientific LLC. He is also on the board of Cleveland BioLabs, Inc. and Director-Connecticut Region at Anti-Defamation League and Portfolio Manager at Mortar Rock Capital LP. In his past career Mr. Saluck occupied the position of Secretary, Chief Financial & Strategic Officer at Accelerated Pharma, Inc., Portfolio Manager at Mortar Rock Capital Management LLC, Portfolio Manager at Meisenbach Capital Management, Inc., Senior Analyst at Highfields Capital Management LP, Senior Analyst at Tyndall Management LLC and Investment Banker at Salomon Brothers. Mr. Saluck received an undergraduate degree from the University of Pennsylvania, an MBA from The Wharton School of the University of Pennsylvania and a graduate degree from the University of Virginia School of Law.
Ann Lenich Hards Ann Lenich Hards is Executive Vice President-Regulatory Affairs at Cleveland BioLabs, Inc. In the past she was President-Pharmaceutical Development at Bridging Health-Matters, LLC, Manager-Regulatory Affairs at Pharmacia, Inc., Vice President-Worldwide Cardiovascular at Sanofi-Aventis, Inc., Executive Vice President-Regulatory Affairs at ARCA biopharma, Inc. and Associate Director-Regulatory Affairs at Somatix Therapy Corp. Ann Lenich Hards received an undergraduate degree from Purdue University and a doctorate from the University of Colorado Health Sciences Center.
Yakov Kogan Founder of Cleveland BioLabs, Inc., Yakov Kogan holds the position of Chief Executive Officer for Panacela Labs, Inc., CEO, Principal Financial Officer & Secretary at Cleveland BioLabs, Inc., Chief Operations Officer of Genome Protection, Inc. and Director & Principal Business Officer at Kadvax Technologies, Inc. In his past career Dr. Kogan was Senior Scientist at ThermoGen, Inc., Director-Business Development for Integrated Genomics, Inc. and Research Associate at The University of Chicago. He received a graduate degree and a doctorate from Moscow State University, an MBA from The University of Chicago Booth School of Business and a doctorate from VNII Ekonomiki Selskogo Khozaystva.
Langdon L. Miller Langdon L. Miller holds the position of President & Chief Medical Officer at Cleveland BioLabs, Inc. and Chief Medical Officer & Executive Vice President at VelosBio, Inc. He is also on the board of Dunn Gardens. He previously held the position of Chief Medical Officer for PTC Therapeutics, Inc., Vice President-Clinical Research Oncology at Gilead Sciences, Inc. and Executive Vice President-Research & Development at Calistoga Pharmaceuticals, Inc. (a subsidiary of Gilead Sciences, Inc.), Vice President-Global Clinical Research at Pharmacia Corp. and Principal at National Cancer Institute. He received a doctorate from Northwestern University.
Anna Evdokimova Anna Evdokimova is Director-Investment & Venture Capital at Millhouse LLC and on the board of 10 other companies. In her past career Ms. Evdokimova occupied the position of Head-Corporate Finance at Slavneft-Yaroslavnefteproduct JSC and Head-Export Finance at Sibneft OAO Siberian Oil Co. She received an undergraduate degree from Moscow State Linguistic University and an MBA from Fordham University.
Daniil Talyanskiy Daniil Talyanskiy is on the board of Cleveland BioLabs, Inc., Affitech An and OncoTartis LLC and Chief Business Officer & Deputy CEO at International Biotech Center Generium, LLC and Director & Deputy Chief Executive Officer at Generium Zao. In his past career he was Head-Corporate University at Oboronprom United Industrial Corp. JSC. Daniil Talyanskiy received a graduate degree from Togliatti Academy of Management.
Anna Evdokimova Anna Evdokimova is Director-Investment & Venture Capital at Millhouse LLC and on the board of 10 other companies. In her past career Ms. Evdokimova occupied the position of Head-Corporate Finance at Slavneft-Yaroslavnefteproduct JSC and Head-Export Finance at Sibneft OAO Siberian Oil Co. She received an undergraduate degree from Moscow State Linguistic University and an MBA from Fordham University.
Lea Verny Currently, Lea Verny occupies the position of Independent Non-Executive Chairman at Zoltav Resources, Inc. and Chairman of Cleveland BioLabs, Inc. In her past career she held the position of Head-Investment Banking at HSBC Bank RR LLC and Director-Corporate Finance at HSBC Bank Plc. Ms. Verny received an MBA from INSEAD and an undergraduate degree from The Hebrew University of Jerusalem.
Alexander Andryushechkin Currently, Alexander Andryushechkin is Chief Financial Officer for International Biotech Center Generium, LLC and Chief Financial Officer & Director at Generium Zao. Mr. Andryushechkin is also on the board of Cleveland BioLabs, Inc., Affitech An and Kirov Plasma JSC. Mr. Andryushechkin previously held the position of Chairman at Astor OOO and Head-Finance at ASG LLC. Mr. Andryushechkin received a graduate degree from Omsk State University Dostoyevskogo and a graduate degree from Omsk State University Dostoyevskogo.
Randy Steven Saluck Founder of Mortar Rock Capital Management LLC, Randy Steven Saluck presently holds the position of Chief Executive Officer of Libertas Funding LLC and Chief Financial Officer & Director at Convexity Scientific LLC. He is also on the board of Cleveland BioLabs, Inc. and Director-Connecticut Region at Anti-Defamation League and Portfolio Manager at Mortar Rock Capital LP. In his past career Mr. Saluck occupied the position of Secretary, Chief Financial & Strategic Officer at Accelerated Pharma, Inc., Portfolio Manager at Mortar Rock Capital Management LLC, Portfolio Manager at Meisenbach Capital Management, Inc., Senior Analyst at Highfields Capital Management LP, Senior Analyst at Tyndall Management LLC and Investment Banker at Salomon Brothers. Mr. Saluck received an undergraduate degree from the University of Pennsylvania, an MBA from The Wharton School of the University of Pennsylvania and a graduate degree from the University of Virginia School of Law.
Ivan Fedyunin Ivan Fedyunin is on the board of Cleveland BioLabs, Inc. and 4 other companies. Dr. Fedyunin previously occupied the position of Chief Operating Officer for Promogen-MAT LLC and Director-Research & Development at Pharmapark LLC. He received a doctorate from the University of Potsdam and an undergraduate degree from Moscow State University Lomonosov.

量化对比

全部评论 4

  • 美股抗疫概念股盘前走强,阿索尔达生物制药涨超110%,克利夫兰生物实验室涨36%,Corbus Pharmaceuticals涨近5%,Moderna涨近3%。

  • 美股抗疫概念板块涨跌不一,联合保健产品跌40%,Alpha Pro Tech跌超29%,克利夫兰生物实验室跌超23%,诺瓦瓦克斯跌超22%;吉利德科学涨超6%,Moderna涨超10%。

  • 美股抗疫概念股盘中转跌,整体跌幅逾20%。吉利德科学跌6%,Alpha Pro Tech跌10%,克利夫兰生物实验室跌15%。

  • 【道指开盘跌3.4%,标普500跌3.2%,纳指跌4.2%】航空股,油气股集体下挫,黄金股大涨。新冠病毒治疗相关概念股集体飙升,NanoViricides涨52.7%,克利夫兰生物实验室涨13.1%,Inovio涨9.2%,Co-Diagnostics涨10.1%,吉利德科学涨6.5%,口罩股Alpha Pro涨19.5%。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐